期刊文献+

CREPT与CyclinD3在非小细胞肺癌中的表达及相关性研究 被引量:2

Expression and correlation of CREPT and CyclinD3 in non-small cell lung cancer
下载PDF
导出
摘要 目的:检测CREPT(cell-cycle related and expression-elevated protein in tumor)与细胞周期蛋白D(CyclinD3)在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达,分析二者在促进NSCLC发生发展过程中的作用。方法:免疫组织化学法检测CREPT、CyclinD3在271例NSCLC及相应正常组织中的表达情况,统计学分析二者间的相关性及其在临床病理因素中的差异性。结果:CREPT和CyclinD3定位于细胞核与细胞质中,在NSCLC组织中高表达,癌组织与正常组织中阳性表达率差异性极显著(P<0.001)。CREPT、CyclinD3在腺癌、鳞癌间表达无统计学差异(P=0.638,P=0.503);在总NSCLC、腺癌、鳞癌的病理分级间,表达均具有极显著性差异(P<0.001);在总NSCLC组织TNM分期、淋巴结是否转移间的表达差异性显著(P=0.025,P=0.001;P=0.003,P=0.026);在总NSCLC、腺癌、鳞癌中,CREPT和CyclinD3表达秩相关系数r分别是0.458、0.393、0.468;P<0.001,二者具有正相关性。结论:CREPT和CyclinD3是NSCLC组织与相应正常组织表达的差异蛋白,二者的过表达可能在NSCLC的发生发展过程中起作用。 Objective: To investigate the expression of CREPT and CyclinD3 in NSCLC, and the role of them in NSCLC occurrence and development process. Methods: The expression of CREPT and CyclinD3 in 271 pairs of NSCLC and corresponding normal tissues were detected by immunohistochemical method. The correlation between CREPT and CyclinD3 expression as well as the difference in clinico-pathological parameters were analyzed by statistical method. Results: Positive staining of CREPT and CyclinD3 were in cytoplasm and nucleus. The positive expression rates of the CREPT and CyclinD3 protein in NSCLC was significantly higher than those in the corresponding normal tissue (all P〈0.001). qlle expression of CREPT and CyclinD3 were no significant differences in among groups of lung adenocarcinoma and squamous cell lung cancer (P=0.638; P=0.503), but there were extremely significant difference in pathological grading groups ofNSCLC, adenocarcinoma, squamous cell carcinoma (all P〈0.001). There were significant difference in the CREPT and CyclinD3 expression among various groups of clinical stages and lymph node metastasis or not (P=0.025, P=0.001; P=0.003, P=0.026). The protein expression level of CREPT was positively related with that of CyclinD3 in NSCLC, adenocarcinoma, squamous cell carcinoma(r=0.458, r=0.393, r=0.468; all P〈0.001). Conclusion: Our data suggest that CREPT and CyclinD3 were differentially expressed proteins in NSCLC tissues and corresponding normal tissues and those over-expressed proteins being crucial for NSCLC occurrence and development
出处 《临床与病理杂志》 CAS 2015年第1期48-53,共6页 Journal of Clinical and Pathological Research
关键词 非小细胞肺癌 CREPT CyclinD3 non-small cell lung cancer CREPT CyclinD3
  • 相关文献

参考文献4

二级参考文献50

  • 1De Yun Feng,Hui Zheng,Yi Tan,Rui Xue Cheng Department of Pathology, Hunan Medical University, Changsha 410078, Hunan Province, China New England Biolab, MA, USA.Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance[J].World Journal of Gastroenterology,2001,7(1):33-36. 被引量:76
  • 2Ming-Yao Wu Mao-Huai Chen Ying-Rui Liang Guo-Zhao Meng Huan-Xing Yang Chu-Xiang Zhuang Department of Pathology,Shantou University Medical College,Shantou 515031,Guangdong Province,China Supported by the National Natural Science Foundation of China,No.39670298..Experimental and clinic-opathologic study on the relationship between transcription factor Egr-1 and esophageal carcinoma[J].World Journal of Gastroenterology,2001,7(4):490-495. 被引量:20
  • 3Min Su~1 Shan-Ming Lu~1 Dong-Ping Tian~1 Hu Zhao~1 Xiao-Yun Li~2 De-Rui Li~3 Zhi-Chao Zheng~4 1 Department of Pathology,2 Tumor Hospital,3,4 Second Teaching Hospital,Shantou University Medical College,Shantou 515031,China.Relationship between ABO blood groups and carcinoma of esophagus and cardia in Chaoshan inhabitants of China[J].World Journal of Gastroenterology,2001,7(5):657-661. 被引量:20
  • 4《2009年中国卫生统计年鉴》:2008年甲乙类法定报告传染病发病及死亡数排序[EB/OL].http://www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year2009/t-9.htm. 被引量:2
  • 5Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59(4): 225-249. 被引量:1
  • 6De Petris L, Crino L, Scagliotti GV, et al. Treatment of advanced non-sman celllung cancer. Ann Oncol, 2006, 17(Suppl2): 36-41. 被引量:1
  • 7Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000, 18(10): 2095-2103. 被引量:1
  • 8Martin H, Cohen, Grant A, et al. United States food and drug administration drug approval summary: gefitinib (ZD1839; Iressa). Clin Cancer Res, 2004, 10(4): 1212-1218. 被引量:1
  • 9Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer.J Clin Oncol, 2003, 21(12): 2237-2246. 被引量:1
  • 10Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290(16): 2149-2158. 被引量:1

共引文献36

同被引文献2

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部